Rock Creek Group, LP Vertex Pharmaceuticals Inc Transaction History

Rock Creek Group, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$234.96 - $292.55 $10,338 - $12,872	-44 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$221.42 - $260.97 $722,714 - $851,806	-3,264 Reduced 98.67%	44 $11,000
Q4 2021 Feb 11, 2022	BUY	$177.01 - $223.45 $585,549 - $739,172	3,308 New	3,308 $803,000
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $1,813 - $2,029	-10 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$187.49 - $221.1 $1,874 - $2,211	10 New	10 $2,000
Q4 2020 Feb 12, 2021	SELL	$207.01 - $276.09 $61,688 - $82,274	-298 Closed	0 $0
Q3 2020 Oct 30, 2020	SELL	$255.65 - $303.1 $36,557 - $43,343	-143 Reduced 32.43%	298 $81,000
Q2 2020 Aug 13, 2020	BUY	$225.48 - $295.8 $99,436 - $130,447	441 New	441 $128,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Rock Creek Group, LP, based on Form 13F filings with the SEC.

Stay updated on Rock Creek Group, LP with notifications on news.